

Supplementary materials




Figure S1 Continued




Figure S1 Continued




Figure S1 Expression analysis of PER in tumor tissues. (A) PER1, (B) PER2, (C) PER3.




Figure S2 Continued




Figure S2 Expression analysis of CRY in tumor tissues. (A) CRY1, (B) CRY2.




Figure S3 Continued




Figure S3 Continued




Figure S3 Continued




Figure S3 Continued




Figure S3 Continued




Figure S3 Immune-associated analysis and tumor mutational burden of PER. (A) PER1, (B) PER2, (C) PER3.




Figure S4 Continued




Figure S4 Continued




Figure S4 Continued




Figure S4 Immune-associated analysis and tumor mutational burden of CRY. (A) CRY1, (B) CRY2.




Figure S5 Continued




Figure S5 PER and prognosis of cancer. (A) PER1, (B) PER2, (C) PER3.




Figure S6 CRY and prognosis of cancer. (A) CRY1, (B) CRY2.